title: How should clinical data be included in experimental studies of cancer immunology?
abstract: Patients diagnosed with the same malignant disease are often heterogeneous with regard to age, complications, malignant cell morphology and tumor histology, disease stage, prognostic parameters, and previous therapy. Many of these factors can affect immunocompetent cells or influence the malignant cell susceptibility to immunotherapy. Summaries of relevant clinical information should therefore be included in cancer immunology studies to increase the present as well as the future scientific impact. Guidelines for selection of relevant information are suggested in the article.
authors.affiliation: University of Bergen, Norway.
authors.forename: Bjørn Tore
authors.initials: BT
authors.lastname: Gjertsen
authors.forename: Øystein
authors.initials: Ø
authors.lastname: Bruserud
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012107:Research Design
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines